MedTrace Logo

Comparing The PK Of Aramchol Meglumine Granules To Aramchol Free Acid Tablets

NCT06502561 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2025-11-17

No results posted yet for this study

Summary

This is a Phase 1 Relative Bioavailability Study Comparing The Pharmacokinetics Of Aramchol Meglumine Granules For Oral Suspension To Aramchol Free Acid 300 mg Tablets In Healthy Volunteers

Conditions

  • Healthy

Interventions

DRUG

Aramchol meglumine

Aramchol meglumine is a salt form of Aramchol free acid

DRUG

Aramchol free acid

Aramchol free acid is a fatty acid-bile acid conjugate

Sponsors & Collaborators

  • Galmed Pharmaceuticals Ltd

    lead INDUSTRY

Principal Investigators

  • Vladimir Gliut, MD · Project management

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-02-15
Primary Completion
2025-06-15
Completion
2025-12-31
FDA Drug
Yes

Countries

  • Bulgaria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06502561 on ClinicalTrials.gov